Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim reported positive results from a similar phase 3 trial assessing its PDE4B ...

People with type 2 diabetes who take GLP-1 and SGLT-2 medications have a lower risk of having COPD symptom flare-ups than ...

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Research and Development (R&D) Expenses: R&D expenses were $82.8 million for the fourth quarter of 2024, compared to $77.5 million for the fourth quarter of 2023, and $301.3 million for the full year ...

Researchers were originally studying sildenafil as a potential treatment for high blood pressure. However, during clinical ...

Inhibiting GLS1 reduced high blood pressure in the right side of the heart of PAH rats and improved various measures of heart ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.3cY8rBmp.js ...

Bosentan 32mg tablets is used for the treatment of pulmonary arterial hypertension. This drug is usable for children aged 3 ...

There is currently no cure for dementia. However, there are treatments and support services that can help someone with the condition. These include drug and non-drug treatments, support, activities, ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

The HYPERION study will be stopped early due to positive efficacy data from across the sotatercept clinical program.